CD6-Targeted Antibody-Drug Conjugate As a Potential Therapeutic Agent for T Cell Lymphomas

Introduction: Peripheral T-cell lymphomas (PTCLs) comprise a subset of blood cancers that are molecularly heterogeneous and often associated with poor survival. While brentuximab vedotin has shown efficacy in CD30-expressing lymphomas such as anaplastic large cell lymphoma, effective targeted therap...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.1193-1193
Hauptverfasser:	Parameswaran, Neetha, Luo, Liping, Zhang, Lingjun, Chen, Joel, Fox, David A, Hsi, Eric D., Jagadeesh, Deepa, Lin, Feng
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!